Al Sandrock (Biogen via Youtube)

'I bleed Bio­gen': Just months af­ter the big biotech was slammed fol­low­ing the con­tro­ver­sial OK of ad­u­canum­ab, R&D chief Al San­drock makes an abrupt ex­it

Two years af­ter Al San­drock jumped from CMO to the top post in R&D — and just months af­ter the hy­per-con­tro­ver­sial ap­proval of the ex­per­i­men­tal Alzheimer’s drug ad­u­canum­ab (Aduhelm) — San­drock is plan­ning to step out of his long ca­reer at Bio­gen.

Late Mon­day evening the big biotech put out word that San­drock, a long­time fix­ture in the com­pa­ny af­ter a 23-year stint, is hit­ting the ex­it.

San­drock sent out an ele­giac mes­sage to­day as he moved to the side­lines, which was ob­tained by End­points News. Not­ing he was leav­ing with his “head held high,” San­drock not­ed:

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.